Pharmather Holdings Ltd
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia… Read more
Pharmather Holdings Ltd (PHRRF) - Total Assets
Latest total assets as of November 2025: $979.77K USD
Based on the latest financial reports, Pharmather Holdings Ltd (PHRRF) holds total assets worth $979.77K USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmather Holdings Ltd - Total Assets Trend (2021–2024)
This chart illustrates how Pharmather Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmather Holdings Ltd - Asset Composition Analysis
Current Asset Composition (May 2024)
Pharmather Holdings Ltd's total assets of $979.77K consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.4% |
| Accounts Receivable | $23.48K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Pharmather Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmather Holdings Ltd's current assets represent 90.3% of total assets in 2024, a decrease from 99.9% in 2021.
- Cash Position: Cash and equivalents constituted 82.4% of total assets in 2024, up from 46.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
Pharmather Holdings Ltd Competitors by Total Assets
Key competitors of Pharmather Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Pharmather Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmather Holdings Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharmather Holdings Ltd is currently not profitable relative to its asset base.
Pharmather Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 7.07 | 4.23 |
| Quick Ratio | 1.77 | 7.07 | 4.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $343.08K | $ 1.35 Million | $ 814.01K |
Pharmather Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Pharmather Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.25 |
| Latest Market Cap to Assets Ratio | 2.17 |
| Asset Growth Rate (YoY) | -59.0% |
| Total Assets | $2.59 Million |
| Market Capitalization | $5.62 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharmather Holdings Ltd's assets at a significant premium ( 2.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pharmather Holdings Ltd's assets decreased by 59.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmather Holdings Ltd (2021–2024)
The table below shows the annual total assets of Pharmather Holdings Ltd from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-05-31 | $2.59 Million | -58.96% |
| 2023-05-31 | $6.31 Million | -48.13% |
| 2022-05-31 | $12.16 Million | +104.64% |
| 2021-05-31 | $5.94 Million | -- |